---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-159833"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T07:57:05.893563+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acadia shareholders elect three Class I directors, approve say-on-pay, and ratify EY as auditor on annual basis

## Summary
- Elected James M. Daly, Edmund P. Harrigan, and Adora Ndu as Class I directors (for votes: 108.2M, 126.2M, 131.6M).
- Advisory say-on-pay approved with 87.3M for vs. 48.3M against; broker non-votes 9.9M.
- Stockholders favored annual advisory vote on executive compensation (135.1M votes for 1 year); board adopts annual frequency.
- Ratification of Ernst & Young as independent auditor for FY2023 approved (144.9M for, 0.5M against, 0.1M abstain).

## SEC filing metadata
- accession: 0001193125-23-159833
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312523159833/0001193125-23-159833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312523159833/d474410d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-159833
- JSON: https://secwatch.observer/filing/0001193125-23-159833.json
- Plain text: https://secwatch.observer/filing/0001193125-23-159833.txt

## Key facts
- Shareholder Votes
  ACADIA PHARMACEUTICALS INC shareholders approved Election of three Class I directors at the 2023-06-01 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: The following three Class I directors were elected by the votes indicated: For Withheld Broker Non- Votes James M. Daly 108,235,140 27,416,787 9,880,431 Edmund P. Harrigan 126,226,342 9,425,585 9,880,431 Adora Ndu 131,558,098 4,093,829 9,880,431
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523159833/0001193125-23-159833-index.htm
- Shareholder Votes
  ACADIA PHARMACEUTICALS INC shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-06-01 meeting.
  - Proposal: say on pay frequency
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: the indication, on an advisory basis, of the preferred frequency of stockholder advisory votes on the compensation of the Company’s named executive officers, which received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 135,140,475 54,863 345,208 111,380 9,880,432
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523159833/0001193125-23-159833-index.htm
- Shareholder Votes
  ACADIA PHARMACEUTICALS INC shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the following vote: For Against Abstain 144,928,829 466,591 136,938
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523159833/0001193125-23-159833-index.htm
- Shareholder Votes
  ACADIA PHARMACEUTICALS INC shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-01 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-01
  source text: the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 1, 2023, which was approved by the following vote: For Against Abstain Broker Non-Votes 87,274,917 48,257,939 119,071 9,880,431
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523159833/0001193125-23-159833-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.